A recently published white paper titled “The Role of Proteomics in Early Cancer Detection: A Look at Six Core Benefits” touches on the collaborative goal between Luminex and Bio-Techne Corporation. The publication addresses six core benefits of integrating protein biomarkers into the development of early cancer detection assays.

[thumbnail]

The paper notes how new proteomic-based technologies have enabled the identification of potential biomarkers that can be used to improve detection of cancers and tumor progression. Yet in moving robust biomarker panels closer toward clinical utility, research trials need sensitive and highly reproducible immunoassay systems that can simultaneously interrogate large numbers of targets per sample in a short time. That’s where Luminex’s xMAP^® Technology has emerged as a valuable tool. Incorporating multiple non-tumor biomarkers from the xMAP^® platform into a multi-omic early cancer detection assay can potentially enhance sensitivity, specificity, and accuracy, thereby improving early detection and leading to earlier intervention and better patient outcomes.

Below is a summary of the six core benefits of utilizing proteomic-based technologies for early cancer detection:

1. 1. Protein patterns: As cancer progresses, monitoring the patterns of protein expression over time can assist in identifying biomarkers that effectively track disease progression and the response to therapy. By focusing on the immune response, we can potentially detect and intervene in cancer at an earlier stage.

 

1. 1. High sensitivity: Proteomic analysis can help identify specific protein biomarkers associated with different types of cancer, providing highly sensitive detection and potential early warning signs of the disease.

 

1. 1. Non-invasive sampling: Many protein biomarkers can be detected through blood, urine, or saliva. Such non-invasive sample collection makes it feasible to perform regular screenings and monitor high-risk individuals more effectively while reducing patient discomfort.

 

1. 1. Practical implementation: Proteomic profiling can identify and characterize proteins indicative of early-stage cancer and can readily serve as targets for diagnostic tests or potential therapeutic interventions. Incorporating protein biomarkers into multi-omics assays increases the potential for practical implementation in routine clinical settings.

 

1. 1. Early intervention: Recent advances in proteomic-based technologies have led to progress in developing tools for early diagnosis, such as certain protein signatures that can help predict the likelihood of disease progression, response to specific treatments, or even the risk of recurrence after initial treatment.

 

1. Protein abundance: Protein biomarkers can be derived from tumor cells, tumor microenvironment, or other tissues affected by cancer. When released into the bloodstream or other bodily fluids, these protein biomarkers provide a broader range of potential targets for early cancer detection.

The collaborative goal: Luminex Corporation and Bio-Techne partnership

Multi-omic approaches offer valuable information in early cancer detection, providing a more comprehensive understanding of cancer biology and may help make diagnostic testing more accurate and actionable.

This innovative partnership between Luminex and Bio-Techne Corporation combines the world’s leading antibody, protein, and ELISA manufacturer with the world’s leading platform for multiplex proteomics—with the joint mission to accelerate the development and commercialization of early cancer detection assays and ultimately improve patient outcomes.

We encourage you to download this white paper for a more in-depth analysis of the role of Luminex’s xMAP Technology in cancer biomarker research and to also check out our Luminex Licensed Technologies Partner program to learn the benefits of becoming a partner.